CRISPR激活逆转TTN截短变异导致的单倍剂量不足与功能缺陷
该研究利用dCas9-VPR CRISPR激活系统,在携带扩张型心肌病相关TTN截短变异的人诱导多能干细胞来源心肌细胞及3D心脏微组织中,通过靶向TTN启动子或三维染色质邻近调控元件,恢复TTN蛋白水平,并改善肌节含量与收缩功能,支持单倍剂量不足为TTN截短变异的致病机制。
要点
- CRISPR激活可恢复TTN截短变异导致的TTN蛋白缺陷。
- TTN蛋白水平升高可正常化肌节含量与收缩功能,即使截短TTN蛋白增加。
- 该策略有望治疗大部分TTN截短变异相关扩张型心肌病。
核心结论
- CRISPR激活TTN可挽救TTN截短变异相关功能缺陷,支持单倍剂量不足为致病机制。
- CRISPR激活有潜力成为治疗大部分TTN截短变异的疗法。
研究设计与样本
- 研究采用dCas9-VPR CRISPR激活系统,在人诱导多能干细胞来源心肌细胞和3D心脏微组织中开展。
- 模型携带扩张型心肌病相关TTN截短变异。
- 方法包括指导RNA筛选、琼脂糖凝胶电泳定量TTN蛋白水平与异构体、RNA测序及心肌细胞表观遗传学实验。
主要发现
- 靶向TTN启动子或三维染色质邻近调控元件的CRISPR激活可挽救TTN截短变异干扰的TTN蛋白缺陷。
- 增加TTN蛋白水平可正常化肌节含量与收缩功能,尽管截短TTN蛋白增加。
- CRISPR激活还增加肌原纤维组装相关和肌节相关转录本水平。
临床怎么用
- CRISPR激活可作为治疗TTN截短变异相关扩张型心肌病的潜在策略。
- 针对TTN启动子或调控元件的激活可恢复TTN蛋白并改善功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TTN truncation variants (TTNtvs) are the most common genetic lesion identified in individuals with dilated cardiomyopathy, a disease with high morbidity and mortality rates. TTNtvs reduce normal TTN (titin) protein levels, produce truncated proteins, and impair sarcomere content and function. Therapeutics targeting TTNtvs have been elusive because of the immense size of TTN, the rarity of specific TTNtvs, and incomplete knowledge of TTNtv pathogenicity. METHODS: We adapted CRISPR activation using dCas9-VPR to functionally interrogate TTNtv pathogenicity and develop a therapeutic in human cardiomyocytes and 3-dimensional cardiac microtissues engineered from induced pluripotent stem cell models harboring a dilated cardiomyopathy-associated TTNtv. We performed guide RNA screening with custom TTN reporter assays, agarose gel electrophoresis to quantify TTN protein levels and isoforms, and RNA sequencing to identify molecular consequences of TTN activation. Cardiomyocyte epigenetic assays were also used to nominate DNA regulatory elements to enable cardiomyocyte-specific TTN activation. RESULTS: CRISPR activation of TTN using single guide RNAs targeting either the TTN promoter or regulatory elements in spatial proximity to the TTN promoter through 3-dimensional chromatin interactions rescued TTN protein deficits disturbed by TTNtvs. Increasing TTN protein levels normalized sarcomere content and contractile function despite increasing truncated TTN protein. In addition to TTN transcripts, CRISPR activation also increased levels of myofibril assembly-related and sarcomere-related transcripts. CONCLUSIONS: TTN CRISPR activation rescued TTNtv-related functional deficits despite increasing truncated TTN levels, which provides evidence to support haploinsufficiency as a relevant genetic mechanism underlying heterozygous TTNtvs. CRISPR activation could be developed as a therapeutic to treat a large proportion of TTNtvs.
引用
- Ghahremani S, Kanwal A, Pettinato A, et al. CRISPR Activation Reverses Haploinsufficiency and Functional Deficits Caused by TTN Truncation Variants. Circulation. 2024. PMID: 38235591. doi:10.1161/CIRCULATIONAHA.123.063972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。